We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 39

Stem cell news - EPO revokes ‘Brüstle’ patent and new CJEU referral on the patentability of parthenotes

  • D Young & Co
  • -
  • European Union, Germany, United Kingdom
  • -
  • June 4 2013

As previously reported in this newsletter (1), the question of the patentability of technology based on the use of human embryonic stem cells (hESC

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Federal Court of Justice: extended advertising options for the pharmaceutical industry

  • Baker & McKenzie
  • -
  • Germany
  • -
  • March 26 2013

In its judgment dated 2 February 2013 (I ZR 6211) the German Federal Court of Justice (BundesgerichtshofBGH) extended the advertising options for

Amendments to German Drug Advertising Act

  • Baker & McKenzie
  • -
  • Germany
  • -
  • March 26 2013

Amendments have been made to the German Drug Advertising Act (HeilmittelwerbegesetzHWG) (Act) by the so-called "Second Act Amending Drug Law and

FSC decides on patentability of neural progenitor cells II (Brustle)

  • Bird & Bird
  • -
  • Germany
  • -
  • February 25 2013

Recently, the German Federal Supreme Court decided on a nullity action on the patentability of progenitor cells extracted from human embryonic stem

German Supreme Court finally finds patent on embryonic stem cell technology valid under reasonable terms while the position of the EPO is still open

  • Prüfer & Partner GbR
  • -
  • European Union, Germany
  • -
  • February 1 2013

Following the preliminary ruling of the Court of Justice of the European Union (CJEU; case C-3410), the long awaited final decision of the German

German court re-enforces incentives ban against manufacturer: no touchpads for increased sales

  • Jones Day
  • -
  • Germany
  • -
  • December 6 2012

Medical device manufacturers whose products more closely resemble consumer goods may be inclined to lose sight of German health care compliance legislation

Joint Senate of the Federal Court of Justice rules: German prescription drug price maintenance also applies to EU mail service pharmacies

  • Oppenhoff & Partner Rechtsanwälte
  • -
  • Germany
  • -
  • September 28 2012

Europa Apotheek, the second largest mail service pharmacy in Europe with its seat in the Netherlands, had offered drugs via Internet mail commerce also for the German market

Gifts and favours to doctors are not a criminal offence

  • CMS Hasche Sigle
  • -
  • Germany
  • -
  • August 28 2012

The Federal Court of Justice has ruled that it is not a criminal offence for German doctors who have their own practice and are authorised to treat patients insured with a statutory healthcare fund to accept favours or gifts from pharmaceutical companies in return for prescribing particular drugs and medication

AG opinion on medical devices qualification issues for e-health software products

  • CMS Cameron McKenna
  • -
  • European Union, Germany
  • -
  • May 21 2012

On 15 May 2012, the Advocate General published his Opinion in the European Court of Justice reference in Brain Products GmbH v BioSemi VOF and Others by the German Supreme Court (Bundesgerichtshof

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy